Latest News

Discover how Nutrafol Men 50+ addresses age-related hair loss in men, combining targeted ingredients for optimal scalp health and hair quality.

UCB shares 3-year BIMZELX (bimekizumab) data in HS, showing sustained hidradenitis suppurativa lesion clearance and major severity reductions.

Catch up on the latest research posters presented at last month's conferences, compiled all in one place for dermatology professionals.

La Roche-Posay and the Oncology Nursing Society mark World Cancer Day with a first-of-its-kind tool, improving cancer care in patients with skin of color.

Clinicians assess chronic urticaria prevalence and impact, revealing gaps in understanding and treatment that affect patient care and outcomes.

Explore innovative treatments for skin conditions, including lebrikizumab for pemphigus and low-level laser therapy for hair loss.

Almirall's sarecycline gains NMPA approval in China, offering a new oral treatment for moderate-to-severe acne, enhancing patient access and outcomes.

AbbVie seeks FDA and EMA approval for upadacitinib, a potential breakthrough systemic treatment for non-segmental vitiligo in adults and adolescents.

The new therapy targets age-related hair loss with a unique formula, promoting thicker, healthier hair for men over 50.

Fractional CO₂ laser treatment effectively reduces acne scars in Middle Eastern patients, balancing safety and efficacy for darker skin types.

Patient education and partner involvement significantly enhance melanoma detection, especially in underserved and skin-of-color populations, improving survival outcomes.

Explore the long-term efficacy of biologics for HS, highlighting bimekizumab's superior outcomes in managing this chronic condition.

Galderma's relabotulinumtoxinA (Relfydess) aims to revolutionize wrinkle treatments with rapid results and lasting effects, pending FDA approval.